Arcturus Therapeutics Hits 52-Week Low at $6.02 Amid Major Decline

Arcturus Therapeutics Holdings, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 6.02 as of November 19, 2025. This significant decline reflects a challenging year for the company, which has seen its stock price plummet by 81.06% over the past year, contrasting sharply with the S&P 500's performance of 12.28% during the same period.
The company's financial metrics indicate ongoing difficulties, with a negative return on equity of -10.01% and a debt-to-equity ratio of -1.07. Arcturus has reported a decline in net sales of 3.8%, with recent quarterly results showing a net sales figure of USD 24.51 million, down 25.31%. Additionally, the pre-tax profit for the quarter was reported at USD -5.35 million, reflecting a 64.11% decrease.

With a market capitalization of USD 484 million, Arcturus Therapeutics continues to face headwinds, as evidenced by its negative EBITDA and underperformance relative to broader market indices. The stock's previous 52-week high was USD 24.14, highlighting the extent of its recent downturn.